Introduction {#Sec1}
============

An unidentified pneumonia outbreak was first observed in Wuhan, the capital of Hubei Province, China, in December 2019 \[[@CR1], [@CR2]\]. WHO officially named the virus Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and the disease, Coronavirus Disease 2019 (COVID-19) \[[@CR3]\], and on Mar 11, 2020, declared COVID-19 as pandemic \[[@CR4]\]. As on 4 May, 2020, there were 3,435,894 confirmed cases globally with 239,604 deaths globally \[[@CR5]\].

Coronavirus is an enveloped, non-segmented, positive-sense single-stranded RNA virus with genome size ranging from 26 to 32 kilobases (the largest known viral RNA genome) \[[@CR6]\]. COVID-19 is mainly transmitted by droplets and contact with contaminated surfaces or objects, showing human-to-human transmission, family aggregation spread, and nosocomial infection \[[@CR7]\]. It is worth noting that COVID-19 has a diverse clinical presentation, ranging from asymptomatic infection to mild respiratory illness to more severe complications of pneumonia, Acute Respiratory Distress Syndrome requiring intensive care unit (ICU) admission, and mechanical ventilation.

While current research is focusing on outcomes and vaccine-development and therapeutics for COVID-19, there remain gaps in our understanding of the natural history of this disease. Recently, published observational studies have provided insights on the epidemiology of this pandemic, but there are limitations in the sample sizes and geographical locations for any definitive conclusions. Hence, we sought to conduct a pooled analysis of the current literature on COVID-19 providing an insight on the epidemiological and clinical characteristics of 6635 patients globally, while also studying image findings and comorbidities.

Methods {#Sec2}
=======

Objectives {#Sec3}
----------

The primary aim of this study was to evaluate the epidemiological and clinical characteristics of COVID-19 patients while also highlighting the comorbidities and radiological findings.

Search Method and Strategy {#Sec4}
--------------------------

In order to evaluate the primary aim, we performed a systematic review of these observational studies, case series, and case reports according to PRISMA guidelines \[[@CR8]\]. We searched the PubMed database for peer-reviewed published articles that reported cases with real-time reverse transcriptase polymerase chain reaction (rRT-PCR)--confirmed SARS-CoV-2 infection and have details on demographics, clinical symptoms, imaging features, and coexisting comorbidities. The database was searched from December 1, 2019, to April 27, 2020. The search was conducted using the following keyword/MESH terms: ((COVID-19\[Title/Abstract\]) OR coronavirus \[Title/Abstract\]) OR SARS-CoV- 2\[Title/Abstract\] OR 2019-nCoV \[Title/Abstract\]. All studies that had information on above mentioned characteristics in COVID-19 patients were included. Review articles, opinion articles, and letters or other articles with incomplete information and not presenting original data were excluded. Non-English literature, non-full text, and animal studies were also excluded. Abstracts were reviewed, and articles were retrieved accordingly. Two independent reviewers performed the search and literature screening (NK and HS), with disputes resolved by consensus following discussion with author (IG and RHK). For the ease of understanding, we used a flow diagram to describe literature search and study selection process in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)

Data Collection {#Sec5}
---------------

A prespecified data collection Excel sheet was used to collect the data relating to study characteristics of interest by two authors (NK and HS), and discrepancies were solved by a discussion with author (IG and RHK). The following study characteristics were extracted: publication year, country of origin, sample size, gender, clinical signs and symptoms, comorbidities, radiology findings, treatment utilized, and complications.

Statistical Analysis {#Sec6}
--------------------

All analysis was done in Excel and SAS 9.4. Percentages and means ± standard deviation (SDs) were calculated to describe the distributions of categorical and continuous variables, respectively**.**

Results {#Sec7}
=======

Our search resulted in 817 studies, out of which 617 non-human studies, non-full text and articles with non-English language information were excluded. Two hundred full-text studies were screened and assessed for eligibility; 150 studies with insufficient clinical information were excluded. The final analysis included 50 articles including observational studies, case series, and case reports, presented in [Supplementary Table](#MOESM1){ref-type="media"}, including a total of 6635 patients to study the pattern and variations in the clinical presentation of the COVID-19 disease. Our review included studies from various countries from across the globe, mainly from China followed by the USA, Germany, Italy, Vietnam, Thailand, Canada, Nepal, and Korea.

Epidemiological and Clinical Characteristics (Table [1](#Tab1){ref-type="table"}) {#Sec8}
---------------------------------------------------------------------------------

Out of 6635 confirmed COVID-19 patients, there was higher percentage of male patients (3617 (54.5%)) than female (3007 (45.3%)) and children (11 (0.2%)). In regard to clinical presentation, fever was the most common symptom, seen in 5325 (80.3%) patients, followed by cough (4262 (64.2%)), fatigue/myalgia (2422 (36.5%)), sputum production (1671 (25.2%)), and dyspnea (1187 (17.9%)). Lesser common symptoms include diarrhea in (627 (9.2%)) patients, followed by chills in (477 (7.2%)) patients, followed by nausea/vomiting (343 (5.2%)), nasal congestion (209 (3.1%)), loss of appetite (132 (2.0%)), and rhinorrhea (75 (1.1%)).Table 1Epidemiological and clinical characteristics of confirmed COVID-19 casesVariablesAll patients (*n* = 6635)TotalPercentage (%)Clinical symptomsFever532580.3Cough426264.2Fatigue/Myalgia242236.5Sputum167125.2Shortness of breath118717.9Headache/dizziness85912.9Sore throat6359.6Diarrhea6279.4Chills4777.2Nausea/Vomiting3435.2Nasal congestion2093.1Loss of appetite1322.0Rhinorrhea751.1Chest pain600.9Hemoptysis370.56Impaired consciousness250.38Rigors240.36Conjunctival congestion190.29Impaired taste120.18Impaired smell120.18Impaired vision30.05Ataxia10.02Seizures10.02Imaging findingsComputed tomography (CT) findings165524ComorbiditiesHypertension150422.67Diabetes mellitus84812.78Cigarette smoking3094.66Cardiovascular disease2543.83Pulmonary disease1702.56Cerebrovascular disease731.10Malignancy701.06Chronic kidney disease660.99Gastrointestinal disease530.79Hepatitis B510.77Immunosuppression150.23Obstructive sleep apnea110.17HIV infection30.05Alcohol consumption20.03Organ transplant20.03

Computed tomography (CT) scan was performed on 1655 patients (24.9%), mainly revealed ground glass opacities in the majority of the patients. Few patients showed imaging features of pleural effusion and consolidation involving one or multiple lobes. Most common co-morbidities were hypertension 1504 (22.67%) followed by diabetes mellitus (848 (12.78%)), smoking (309 (4.66%)), pre-existing cardiovascular disease (254 (3.83%)), pulmonary disease (170 (2.56%)), and cerebrovascular disease (73 (1.10%)).

Discussion {#Sec9}
==========

Over the past five months, more than 5 million COVID-19 cases have been confirmed across the globe with nearly 300,000 deaths globally \[[@CR9]\]. COVID-19 is a new clinical disease and an emerging condition alarming the preparedness at different levels. This pandemic urges continuous efforts in various fields of epidemiology, therapeutic and diagnosis, and preventive medicine globally \[[@CR10], [@CR11]\]. In setting of COVID-19 outbreak, many critical questions have arisen regarding disease severity ranging from asymptomatic to mildly symptomatic, to severe requiring ICU admission, to death \[[@CR12]\]. Hence, in this systematic review and pooled analysis of 6635 confirmed COVID-19 cases from across the world, we have summarized critical information regarding epidemiology, clinical symptoms, radiology findings, and coexisting comorbidities of new COVID-19 infectious disease to have greater knowledge of the evolving pandemic.

In our pooled analysis, the most common symptoms of COVID-19 include fever, cough, fatigue/myalgia, sputum, and dyspnea along with other clinical symptoms. These findings of our study align with initial studies from China \[[@CR2], [@CR13], [@CR14]\] and was also observed in all the studies included in this study including case series and case reports. The frequency of fever in COVID-19 is similar to SARS and MERS \[[@CR15]\]; however, diarrhea is reported in 20--25% of SARS and MERS patients \[[@CR16]\], but in our study only 9.2% patients had reported diarrhea. Our study findings are consistent with Rodriguez-Morales et al. \[[@CR17]\] metanalysis of 635 patients, who reported 6.3% of COVID-19 patients with diarrhea. Furthermore, few COVID-19 patients may have mild symptoms, which can be easily overlooked \[[@CR18]\], and few patients may be asymptomatic, which makes it difficult to detect and isolate such carriers on time, further making it difficult to contain the spread \[[@CR19]\]. Interestingly, some of the rare presenting symptoms in our cohort include rhinorrhea, hemoptysis, chest pain, loss of smell, loss of taste, and raising suspicion of COVID-19 disease. Majority of the study patients had co-existing comorbidities, with most common being hypertension, diabetes, and cardiovascular disease. Early identification of such high-risk patients will help in better utilization of health care resources for more severe COVID-19 patients.

COVID-19 disease may have clinical course similar to SARS. However, case--control studies are required to better understand the clinical evolution of the disease \[[@CR20]\]. During the initial stage its presentation is similar to SARS coinciding with the recent viral load data reported by the Zou et al. \[[@CR21]\]. As the disease progress, SARS-CoV-2 affects lower respiratory tract as seen on CT scan of our patient cohort with majority having bilateral ground-glass opacities in the peripheries and mostly in the posterior aspects of lungs. A proportion of patients also exhibit consolidative changes. According to the published literature till date, COVID-19 patients may have typical imaging features including ground-glass opacities, consolidation, enlarged lymph nodes, and cavitating nodules. These lesions can be peripheral or bilateral but help in screening of suspected cases, knowledge of extent of the disease, and managing of the severe cases \[[@CR22]\].

Most of our study findings are consistent with first metanalysis published by Rodriguez-Morales et al., which included articles until February 23, 2020 \[[@CR17]\]. Hence, our study findings have added to the existing literature of epidemiology, clinical characteristics, and common coexisting comorbidities. The biggest strength of our study is that the results are robust due to the pooled analysis of large sample size of 6635 patients after combining all the studies globally. However, our study has few limitations. The clinical data in our study results are mainly from published studies in China. Hence, there is need for more research data from other geographical locations like the USA, Spain, Italy, and others which have faced the surge of the pandemic to explicate the spectrum of the disease and complications in patients with COVID-19 and its associated outcomes based on the large sample size and representing global population.

Conclusion {#Sec10}
==========

This systematic review and pooled analysis of the current literature on COVID-19 provide insight on the epidemiological characteristics and clinical manifestation of the disease with wide range of typical and atypical manifestations of the disease. We also focused on the comorbidities associated with COVID-19 patients, which can help clinicians in early screening of high-risk patients and wise utilization of health care resources in these patients to prevent more severe disease. With the pandemic unfolding, research is the need of the hour. Even with massive amounts of publications, there remain gaps in the understanding of the natural history of the disease. Hence, there is still need for more extensive studies with short- or long-term follow up assessments and with large sample sizes from different countries facing the pandemic other than China to have good characterization of the course of this new COVID-19 disease.
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